Sofosbuvir and velpatasvir
- Generic Name
- Sofosbuvir and velpatasvir
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
1.用于治疗基因1～6型、混合型及未知型慢性丙型肝炎病毒(HCV) 的成人感染患者。
2.美国FDA批准用于治疗6岁及以上或体重超过17千克的6种基因型（GT-1,-2,-3,-4,-5,-6）的HCV儿童感染者（无肝硬化或轻度肝硬化）。
- Associated Conditions
- -
- Associated Therapies
- -
A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 201
- Registration Number
- NCT04075916
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Jackson Memorial Hospital/University of Miami, Miami, Florida, United States
Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 20
- Registration Number
- NCT03818308
- Locations
- 🇩🇪
Allgemeinmedizinische und internistische Praxis, Berlin-Friedrichshain, Germany
🇩🇪Zentrum für Infektiologie Prenzlauer Berg, Berlin, Germany
🇩🇪Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I, Bonn, Germany
Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients
- Conditions
- Human Immunodeficiency VirusHepatitis C Virus Infection, Response to Therapy of
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 228
- Registration Number
- NCT03250910
- Locations
- 🇨🇳
National Taiwan University Hospital, Yun-Lin Branch, Douliu, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.